Given that all trials carry an element of risk, experts believe that there is an "unfair" burden-benefit ratio on the Indian population when sponsors conducting trials in multiple countries recruit too many patients from the country, said the study published in PLOS One journal. "The Indian drug regulator needs to be particularly alert to the planned, or actual, over-recruitment of participants from India," the researchers said in the study.
